Over 200 years of experience
in the pharmaceutical industry
FDF, API, CMO, CDMOPharmaceutical development and manufacturing
-
Contract manufacturing
Learn moreWe specialise in the production of active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). Our production lines for highly potent medicines (OEB 5) are among the most advanced in Central and Eastern Europe. We operate in full compliance with EU cGMP, FDA and EAEU standards.
-
Laboratory services
Learn moreWe offer comprehensive preformulation and analytical support. In 2025, we launched a state-of-the-art laboratory for highly potent parenteral products (OEB 5). Our team performs over 4,000 tests annually.
Over 50 products
in 130 forms and doses
We manufacture prescription (Rx) medicines – antibiotics, human insulins, CNS and dermatological products – as well as over-the-counter (OTC) medicines, dietary supplements and dermocosmetics. Every year, we deliver over 25 million packages to hospitals, pharmacies and healthcare institutions, supporting the health and well-being of patients worldwide.
We manufacture in Poland
– for a safer tomorrow
We are the oldest pharmaceutical company in Poland and one of the oldest in Europe. Since 1823, we have been building the foundations of Polish pharmacy by introducing groundbreaking solutions. We were the first in the country to start producing penicillin, insulin and antibiotics, setting new standards in treatment. Today, we produce 10% of the medicines classified as critical by the European Union, helping to secure treatment access for millions of patients.
News
-
23.10.2025AnnouncementsCenter for Development and Production of Highly Potent Drugs
TZF Polfa, a Polish pharmaceutical manufacturer, proudly presents its latest investment located in Warsaw – the Center for Development and Production of Highly Potent Drugs, one of the most advanced injectable drug manufacturing facilities in Europe. This technologically advanced plant fully responds to the growing global demand for injectable medicines in various pharmaceutical forms. The […] -
01.12.2025AnnouncementsDistribution of PolhuminPen injectors
Dear Patients and Doctors, Please be advised that PolhuminPen® injectors are distributed free of charge exclusively as part of a patient program for individuals requiring insulin therapy. To facilitate access to injectors, doctors can order them online at: 👉 https://tzfpolfapromed.pl/ Thank you for working with us to ensure the comfort and safety of patients! -
23.10.2025AnnouncementsSuccess in the development of the medicinal product Dapagliflozinum 10 mg
We are pleased to announce that the newly developed medicinal product Dapagliflozinum, 10 mg, coated tablets, has successfully passed bioequivalence testing. The project is co-financed from the state budget by the Medical Research Agency as part of project No. 2022/ABM/04/00021 – “Development and advancement of a medicinal product with the active substance dapagliflozin – a […] -
16.10.2025TendersRequest for quotation – RFQZ79/5914/1 – Bioequivalence study: Empagliflozinum, 25 mg, coated tablets
In connection with the implementation of project 2022/ABM/04/00014-00 – “Development and advancement of a medicinal product with the active substance EMPAGLIFLOZIN – a generic drug for type 2 diabetes”, Tarchomińskie Zakłady Farmaceutyczne POLFA S.A. invites tenders for the subject of the contract specified below. The project is co-financed from the state budget as part of […] -
09.10.2025Message for the patientAvailability of Elenium
Warsaw, October 7, 2025 Dear Sir or Madam, In connection with the administrative decision of the Main Pharmaceutical Inspectorate concerning the withdrawal from the market of specific batches of the medicinal product Elenium 5 mg, coated tablets Elenium 10 mg, coated tablets Elenium 25 mg, coated tablets we would like to provide you with the […] -
13.09.2025AnnouncementsDistribution of PolhuminPen injectors
Please note that inquiries regarding the free distribution of PolhuminPen should be sent directly to: wstrzykiwacze@tzf.pl. For more information, please call: +48 (22) 510 80 01.
